#Influenza #Medication #Market #Size
Pune, Oct. 11, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global Influenza Medication Market is expected to clock US$ 1510 million by 2030 and to grow at a CAGR of 4.8% during the forecast period. As an upsurge in cases of influenza is noted annually, which is anticipated to fuel the growth of this market. This exclusive information is published by Growth Plus Reports in its report titled “Influenza Medication Market – Global Outlook & Forecast 2022-2030”
Market Drivers
The global influenza medication market is expected to grow due to factors such as an increase in the number of influenza patients and increased research and development for drug development efforts. Technological advancements that result in a strong pipeline of novel medications may present this market with a growth opportunity.
Get a Sample Copy of the Research Report: https://growthplusreports.com/inquiry/request-sample/influenza-medication-market/7859
Excerpts from ‘By Treatment Type’
The global influenza medication market has been divided into treatment types such as
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Others (Including Zanamivir)
Currently, oseltamivir phosphate dominates the global influenza medication market. The factors influencing the demand for oseltamivir phosphate are the broad prescription of this drug and its high efficacy in treatment. It is also effective in blocking the action of both influenza types, A and B. Oseltamivir phosphate shortens the duration of flu symptoms such as a runny nose, cough, sore throat, fever, and chills. Also, it works by attacking the flu virus and preventing it from multiplying in the human body, thereby reducing the flu symptoms.
Excerpts from ‘By Influenza Type’
Influenza A and Influenza B are two types studied for this scope. Between these, influenza type A captures larger revenue share, due to the high incidence rate. Influenza type A has further variants, which…
